Lewis

Lewis & Clark Pharmaceuticals is a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting adenosine receptors. The company leverages its expertise in medicinal chemistry to create highly selective ligands for the A1, A2A, A2B, and A3 adenosine receptor subtypes. Their primary therapeutic focus areas include the treatment of chronic pain, inflammatory diseases, and respiratory conditions such as asthma and COPD. By modulating these ubiquitous signaling pathways, Lewis & Clark aims to provide more effective and safer alternatives to current standards of care. The company is based in Charlottesville, Virginia, and maintains a pipeline of early-stage candidates.